Other

Paul-Ehrlich-Institut Bundesamt Fur Sera Und Impfstoffe

Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Prof. Dr. Klaus Cichutek

Gerald Schumann

Enrico Garaci

Christian Buchholz

Corrado Spadafora

Ilaria Sciamanna

Chiara De Luca

Liliana Elisabeth Layer

Paola Sinibaldi-Vallebona

Fiorella Guadagni

Irene Schneider

Sabine Klawitter

Liliana Layer

The present disclosure relates to a monoclonal antibody specifically binding to human Long Interspersed Element-1 ORF2 encoded protein (L1-ORF2p) obtained from hybridoma chA1, and derivatives and uses thereof, including for prediction of response of cancer patients to NNRTI treatments. It also relates to a method for early detection of cell transformation in pre-neoplastic tissues of a human subject, comprising detecting in cells of a pre-neoplastic tissue sample from said subject the expression of L1-ORF2p, wherein the expression of L1-ORF2p indicates the presence of cell transformation in said pre-neoplastic tissues. It also relates to a method for detecting progression of colon adenoma in a human subject suffering from colon adenoma, based on detection of an increase of L1-ORF2p expression.

Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject

The invention relates to nucleic acids, vector constructs which allow the controlled activation and inhibition of retrotransposition of non-LTR retrotransposons. The methods of this invention are useful for preparing said nucleic acids and vector constructs and introducing them into cells.

Controlled activation of non-LTR retrotransposons in mammals

Growing community of inventors

Dreieich, Germany

Gerald Schumann